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Abstract
Control theory has seen recently impactful applications in network
science, especially in connections with applications in network medicine.
A key topic of research is that of finding minimal external interventions
that offer control over the dynamics of a given network, a problem known
as network controllability. We propose in this article a new solution for
this problem based on genetic algorithms. We tailor our solution for
applications in computational drug repurposing, seeking to maximise its
use of FDA-approved drug targets in a given disease-specific protein-protein
interaction network. We show how our algorithm identifies a number of
potentially efficient drugs for breast, ovarian, and pancreatic cancer. We
demonstrate our algorithm on several benchmark networks from cancer
medicine, social networks, electronic circuits, and several random networks
with their edges distributed according to the Erdo˝s-Re´nyi, the small-world,
and the scale-free properties. Overall, we show that our new algorithm
is more efficient in identifying relevant drug targets in a disease network,
advancing the computational solutions needed for new therapeutic and
drug repurposing approaches.
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1 Introduction
Network modelling in systems medicine has emerged as a powerful analytics
approach in the last couple of decades ([37, 62, 70]). Its aim is to analyse
diseases and drug interventions as ways of acting, and re-acting, over bio-
medical dynamical networks ([3, 22, 82]), such as the protein-protein interaction
networks ([13, 36]), signalling networks ([57]), metabolic networks ([51]), and
immunological responses ([15]). In this framework, a disease is seen as emerging
from some of its modules being affected (directly or through cascading signals)
and from critical nodes in the network being deregulated ([41]). Similarly,
drug therapies are seen as outside controlled interventions within a deregulated
network with the aim of either re-balancing the system or possibly isolating some
specific components of the network ([7]). A particular advantage of this approach
is reasoning about multiple-drug interventions, analysing and predicting multi-
drug synergies, as well as aiming for personalised therapies. The current “state”
of a patient can be reflected in its personalised network ([70]), by integrating
elements specific to the disease, to treatment pathways, and to the patient herself,
such as genetic mutations and current medical conditions and treatments.
Instead of acting over each individual disregulated component, one can try
to influence several of these entities through a few well-chosen interventions,
and to have them spread in cascade into the network using the network’s own
internal interconnections. It turns out that network controllability is a topic of
high relevance in this area with a rich theory to support it ([35]). It has found
in recent years powerful applications in computational systems medicine and
therapeutics ([43], [36, 13, 79, 42, 21, 26]).
The theory of network controllability aims at providing sound and theoret-
ically accurate description of what control means within a network, and how
it can be achieved. Intuitively, achieving control over a system from a set of
input nodes means being able to drive that system from any initial setup to any
desired state. This is an intrinsic optimisation problem with the objective to
minimise the number of input nodes (e.g., drug targets) needed for the control.
Additional constraints may be added depending on the application, such as the
control pathways from the input nodes to the controlled nodes to be short, or the
input nodes to be primarily selected from a given set of preferred nodes (targets
of standard therapy drugs). This leads to several problem variations, such as:
structural controllability ([43]), i.e., identifying pathways that offer control over
the system regardless of its numerical setup; target controllability ([21]), i.e.,
achieving control over a predefined set of target nodes; minimum dominating sets
([52]), i.e., finding a minimal set of nodes that are one step upstream of all other
nodes in the network. Some of these optimisation problems are known to have
efficient algorithmic solutions ([43]). Others, on the contrary, are known to be
computationally difficult, yet approximate efficient solutions are still achievable
([13]).
Motivated by the applicability of network control in systems medicine, the
problem we focus on in this paper is minimising the number of external in-
terventions needed to achieve target control of a system. We are particularly
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interested in the case where the targets are disease-specific survivability-essential
genes, key targets for synthetic lethality ([60]). We identify control interventions
that are achievable through the delivery of FDA-approved drugs, by giving a
preference to FDA-approved drug targets being selected as input nodes. The
target controllability problem is known to be NP-hard, meaning that finding the
smallest set of inputs for controlling the target set is computationally prohibitive
for large networks. We give as a solution an approximation of the minimal
solution based on genetic algorithms, well known heuristic choices for nonlinear
optimisation problems ([73]). We demonstrate that this approach offers an
efficient solution for applications in combinatorial drug therapy identification
and drug repurposing.
2 Materials and methods
2.1 Network controllability
We introduce briefly the basic concepts of network controllability and the Kalman
condition for the target controllability problem. For more details we refer to
[13]. By convention, all vectors are considered to be column vectors so that the
matrix-vector multiplications are well defined.
Let A ∈ Rn×n be an n × n matrix, for some n > 1. The linear dynamical
system defined by matrix A is an n-dimensional vector x of real functions,
x : R → Rn, defined as the solution of the system of ordinary differential
equations
dx(t)
dt
= Ax(t), (1)
for some given x(0). The structure of a linear dynamical system can be
thought of as an edge-labeled directed graph with n vertices and adjacency
matrix A: for any nodes i, j, 1 ≤ i, j ≤ n, the (directed) edge (i, j) documents
node i being influenced by node j, with the weight of the influence (documented
as the label of edge (i, j)) given by the (i, j) entry ai,j of matrix A.
We consider a subset of input nodes I ⊆ {1, 2, . . . , n}, I = {i1, . . . , im},
1 ≤ m ≤ n, thought of as the nodes of the linear dynamical system on which an
external contribution can be applied to influence the dynamics of the system.
The subset of input nodes I can also be described through its characteristic
matrix BI ∈ Rn×m, defined as follows: BI(r, s) = 1 if r = is and BI(r, s) = 0
otherwise, for all 1 ≤ r ≤ n and 1 ≤ s ≤ m. The external influence is exerted
through an m-dimensional input vector u of real functions, u : R → Rm. The
influence of the input vector u on the linear dynamical system is described by
the equation
dx(t)
dt
= Ax(t) +BIu(t). (2)
We also consider a subset of target nodes T ⊆ {1, 2, . . . , n}, T = {t1, . . . , tl},
m ≤ l ≤ n, thought of as a subset of the nodes of the linear dynamical system
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whose dynamics we aim to control (as defined below) through a suitable choice
of input nodes and of an input vector. The subset of target nodes can also
be defined through its characteristic matrix CT ∈ Rl×n, defined as follows:
CT (r, s) = 1 if tr = s and BI(r, s) = 0 otherwise, for all 1 ≤ r ≤ l and 1 ≤ s ≤ n.
The triplet (A, I, T ) is called the targeted linear dynamical system with
inputs, defined by matrix A, input set I and target set T . We say that this
system is target controllable if for any x(0) ∈ Rn and any α ∈ Rl, there is an
input vector u : R → Rm such that the solution x˜ of (2) eventually coincides
with α on its T -components, i.e., CT x˜(τ) = α, for some τ ≥ 0. Intuitively, the
system being target controllable means that for any input state x0 and any
desired final state α of the target nodes, there is a suitable input vector u driving
the target nodes to α. Obviously, the input vector u depends on x0 and α.
We illustrate in Figure 1 the structural setup of the target controllability
problem.
Figure 1: The structural setup of the target controllability problem. In green:
input nodes. In red: target nodes. The control paths are indicated with thicker
arrows.
The question whether a given targeted linear dynamical system with inputs
(A, I, T ) is controllable has an elegant algebraic answer known as the Kalman
condition.
Theorem 2.1 ([35]). A targeted linear dynamical system with inputs (A, I, T ) is
controllable if and only if its controllability matrix [CTBI , CTABI , CTA
2BI , . . . ,
CTA
n−1BI ] is of full rank.
The controllability matrix of the targeted linear dynamical system with
inputs (A, I, T ) is an l×mn matrix, meaning that being of full rank is equivalent
with its rank being equal to l (since l ≤ mn). Intuitively, this matrix describes
all weighted paths from the input nodes to the target nodes in directed graph
associated to the linear dynamical system described by matrix A. This line of
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thought can be further developed into a structural formulation of the targeted
controllability and into a graph-based solution for it, see [13].
The problem we focus on and solve in this paper is that of minimising the set
of input nodes needed for the target controllability of a dynamical system. For
the linear dynamical system defined by a matrix A ∈ Rn×n and a set of target
nodes T of size l, the problem is to find the smallest m, 1 ≤ m ≤ l, such that
for a suitable input set I of size m, the targeted linear dynamical system with
inputs (A, I, T ) is target controllable.
We add an extra layer of optimisation to the target controllability problem,
motivated by medicine as our application domain. In medical applications,
the input functions mimic the effect of drug delivery, with the input nodes
being targets of commercially available drugs. Consequently, we introduce in
our mathematical formulation an additional set of so-called preferred nodes
P ⊆ {1, 2, . . . , n}, with the aim of selecting in the input set I as many preferred
nodes as possible. The problem in this case becomes the following. For the
linear dynamical system defined by a matrix A ∈ Rn×n, a set of target nodes
T and a set of preferred nodes P , the problem is to find a smallest-sized input
set I whose intersection with P is maximal, such that the targeted linear
dynamical system with inputs (A, I, T ) is controllable, i.e., such that matrix
[CTBI , CTABI , CTA
2BI , . . . , CTA
n−1BI ] is of full rank.
The optimisation version of the above-defined target controllability problem
has been shown to be NP-hard in [36], meaning that an exact solution may
require a prohibitive amount of time, exponential in the number of nodes. We
focus in this paper on the next most-feasible objective, an efficient and effective
heuristic solution that comes, however, with no guarantee of being optimal.
2.2 The outline of the genetic algorithm
The algorithm takes as input a network given as a directed graph G = (V,E)
and a list of target nodes T ⊆ V , T = {t1, . . . , tl}. We denote the graph’s
adjacency matrix by AG. The algorithm gives as a result a set of input nodes
I ⊆ V controlling the set T , with the objective being to minimise the size of
I. The algorithm can also take as an additional, optional input a set P ⊆ V
of so-called preferred nodes. In this case, the algorithm will aim for a double
optimisation objective: minimise the set I, while maximising the number of
elements from P included in I. Our typical application scenario will be that
of a network G consisting of protein-protein interactions specific to a disease
mechanism of interest, with the set of targets T being a disease-specific set of
essential genes, and the set of preferred nodes P a set of proteins targetable
by available drugs or by specially designed compounds (e.g., inhibitors, small
silencing molecules, etc.) The terminology we use to describe the algorithm, e.g.,
population/chromosome/crossover/mutation/fitness is standard in the genetic
algorithm literature and refers to its conventions, rather than being suggestive
of specifics in molecular biology.
Our algorithm will start by generating several solutions to the control problem,
in the form of several control sets I1, . . . , Im – we discuss in Section 2.3 how this
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is achieved. Each such solution is encoded as a “chromosome”, i.e., as a vector
of (not necessarily distinct) “genes” [g1, . . . , gl], where for all 1 ≤ i ≤ l, gi ∈ V
controls the target node ti ∈ T . In particular, gi is an ancestor of ti in graph G,
for all 1 ≤ i ≤ l.
A set of chromosomes is called a population. Note that a chromosome will
always encode a solution to our optimisation problem, throughout the iterative
run of the algorithm. Any population maintained by the algorithm consists of
several such chromosomes, some better than others from the point of view of our
optimisation criteria, but all valid solution to the target controllability problem
to be solved.
The algorithm iteratively generates successive populations (sets of chromo-
somes) that get better at the optimisation it aims to solve: the size of the
control set gets smaller and the proportion of preferred nodes in the control
set gets higher. The algorithm stops after a maximum number of iterations,
or after a number of iterations in which the quality of the solution does not
get improved. This pre-defined stop is necessary since the target controllability
problem is known to be NP-hard and so, finding the optimal solution can require
a prohibitively high number of steps, potentially exponential in the number
of nodes in the network. The end result consists of several solutions to the
problem, represented by all the control sets in the final population obtained by
the algorithm.
The initial population of solutions is randomly generated in such a way that
each element selected for it is indeed a solution to the target controllability
problem (AG, I, T ). To generate the next generation/population from the current
one, we use three techniques.
• Retain in the population the best solutions (from the point of view of the
optimisation problem to be solved). “Elitism” will be used to conserve the
best solutions (discussed in the next sections in details).
• Add random chromosomes (all being valid solutions to the optimisation
problem, albeit potentially of lower fitness score than some of the others
in the population).
• Generate new solutions/chromosomes resulting from combinations of those
in the current population. A selection operator is used to choose the
chromosomes which will produce offsprings for the following generation.
New chromosomes are produced using crossover and mutation (discussed
in the next sections in details).
A list of all the parameters used by the genetic algorithm can be found in
Table 1. The basic outline of the proposed genetic algorithm is described below.
All operators will be detailed in the following subsections.
1. Generate the initial population. We set t← 0 for the first generation. We
initialise P (t) with a number of n randomly generated chromosomes.
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2. Preserve the fittest chromosomes. We evaluate the fitness of all chromo-
somes in P (t). We add to the next population Pt+1 the pe ·n chromosomes
in the current generation with the highest fitness score, where 0 ≤ pe < 1
is the ‘elitism’ parameter. If there are more chromosomes of equal fitness
being considered, the ones to be added are randomly chosen.
3. Add random chromosomes. We add pr · n new randomly generated chro-
mosomes to P (t+ 1), where 0 ≤ pr < 1 is the ‘randomness’ parameter.
4. Add the offsprings of the current population. We apply two times the
selection operator on P (t), obtaining two chromosomes of Pt selected
randomly with a probability proportional to their fitness score. On the
two thus selected chromosomes we apply the crossover operator, obtaining
an offspring to be added to P (t+ 1). The offspring is added in a mutated
form with the mutation probability 0 ≤ pm < 1. We continue applying
this step until the number of chromosomes in P (t+ 1) becomes n.
5. Iterate. If the current index t is smaller than the maximum number of
generations N , then we set t← t+ 1 and we continue with Step 2.
6. Output. We return the fittest chromosomes in the current generation as
solutions to the problem and we stop the algorithm.
2.3 Chromosome encoding and the fitness function
A chromosome I consists of a vector of l genes I = [g1, . . . , gl], not necessarily of
distinct value, where l is the size of the target set T . As discussed before, for all
1 ≤ i ≤ l, gi ∈ V controls node ti ∈ T and so, in particular, it is an ancestor of
ti in graph G. Keeping with our focus on applications in medicine, where paths
encode signalling networks, we aim for short paths between the input nodes gi
and the target nodes ti. The maximum allowed length for such a path is encoded
in the parameter maxpath. Any time we discuss an ancestor g of node t we mean
implicitly that the shortest path from g to t is of length at most maxpath.
A chromosome I = [g1, . . . , gl] is always checked to ensure that the nodes
encoded by its genes are able to control the target set T . This is equivalent
to the Kalman matrix corresponding to graph G, input set I and target set T
having maximum rank l. All populations, throughout all steps of the algorithm,
will consist only of such chromosomes.
The fitness score of a chromosome I is defined as the complement of the
number of distinct nodes encoded by its genes:
f(I) =
(l + 1)− |supp{bi|bi ∈ I}|
l
· 100. (3)
Thus, 0 < f(I) ≤ 100. Considering that we are interested in the smallest
possible number of input nodes, the higher the fitness score of a chromosome,
the better its encoded solution is.
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To generate a random chromosome, we will first initialise each of its l elements
gi, 1 ≤ i ≤ l, with its corresponding target node ti. Then, for a number of
randomly selected genes (as many as indicated by the parameter maxrand), we
will replace gene gi with a randomly chosen ancestor of ti (at distance at most
maxpath from ti). Each vector of nodes generated in this way is checked for its
Kalman condition: if satisfied, the vector encodes a set of nodes controlling the
target set T and it is accepted as a valid output.
2.4 Selection
The selection operator is used to choose which chromosomes in the current
generation will contribute offsprings to the next generation. The selection of
a chromosome depends only on its fitness in relation to the average fitness of
the current generation: the better the fitness, the higher the chance it has to be
selected. If the current population consists of chromosomes I1, . . . , In, then the
probability of selecting chromosome Ii, 1 ≤ i ≤ n is
p(Ii) =
f(Ii)∑n
k=1 f(Ik)
. (4)
Obviously, 0 < p(Ii) < 1 for any 1 ≤ i ≤ n, so all chromosomes have a chance
of being selected.
2.5 Crossover
The crossover operator is used to produce a new (valid) “offspring” chromosome
from two “parent” chromosomes. Each of the offspring chromosome’s genes will
be directly inherited from one of the two parent chromosomes. The actual parent
who will contribute a certain gene is randomly chosen based on the number
of occurrences of that gene in the two parent chromosomes: the more often it
occurs (in other words, the more efficient its control over the target set), the
higher the probability it will be selected for the offspring. For a chromosome
I = [g1, . . . , gl] and a gene g, we define the number of occurences of g in I to be
#I(g) = |{1 ≤ i ≤ l | gi = g}|. Also, for two chromosomes I, I ′, the number of
occurrences of g in I, I ′ is defined to be #I,I′(g) = #I(g) + #I′(g).
Consider the two parent chromosomes to be I1 = [g11, g12, . . . g1l] and I2 =
[g21, g22, . . . g2l]. For all 1 ≤ i ≤ l, gene gi of the offspring will be either g1i or
g2i. If the genes g1i or g2i are either both preferred (i.e., elements of P ), or they
are both un-preferred, then the probability distribution is defined to be
p(g1i) =
#I1,I2(g1i)
#I1,I2(g1i) + #I1,I2(g2i)
, p(g2i) =
#I1,I2(g2i)
#I1,I2(g1i) + #I1,I2(g2i)
. (5)
On the other hand, if one of the two parent genes, say g1i, is a preferred node,
while the other is not, we reflect our preference for nodes in P in the selection
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probability in the following way
p(g1i) =
2 ∗#I1,I2(g1i)
2 ∗#I1,I2(g1i) + #I1,I2(g2i)
, p(g2i) =
#I1,I2(g2i)
2 ∗#I1,I2(g1i) + #I1,I2(g2i)
.
(6)
If the set of nodes obtained as a result of the selection above does not satisfy
the Kalman condition, then we do not accept it as a valid solution and we discard
it, restarting the crossover operator by selecting two new parent chromosomes.
In our numerical experiments, relatively few sets of nodes thus selected failed to
satisfy the Kalman condition and this step did not become a bottleneck in our
algorithm.
2.6 Mutation
The mutation operator is used to change the values of a small number of genes
in a chromosome. The probability for a gene of a chromosome to be selected
for mutation is given by the parameter 0 ≤ pm < 1. Thus, on average, each
newly generated offspring chromosome will have a number of pm × l mutated
genes. Each gene gi, 1 ≤ i ≤ l represents an ancestor of its corresponding target
node ti, so gi getting mutated corresponds to replacing it with another ancestor
of ti; the option of getting gi again is allowed. The new ancestor is selected
randomly from the set of predecessors of ti, with those being preferred nodes
having double the weight.
If the newly obtained chromosome is not valid according to the Kalman
condition, then we repeat the process with the same genes selected for mutation.
2.7 Implementation
The proposed algorithm has been implemented as a cross-platform stand-alone
desktop application written in C# / .NET Core and usable within a command-
line interface or under a browser-based graphical interface. The source code and
the latest release are available at [59].
For each run, the software requires several files – one containing the list of
directed edges (by default, each edge on a separate row, containing semicolon-
separated source and target nodes), the list of target nodes (by default, each
node on a separate row) and the set of parameters in Table 1 (by default, as
a JSON file). The required format for each of these files is presented in the
supplementary information. In addition, a file containing the list of preferred
nodes (by default, each node on a separate row) can also be given as an optional
input. For the command-line interface, the input data is provided as paths to
the corresponding input files. For the graphical user interface, the same options
are available, with the added possibility to directly type in or edit the data
within the corresponding text fields of the interface. Both cases return the same
type of output data, a JSON file containing all of the relevant information of
the algorithm run, such as details about the input data, the used parameters,
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the time elapsed and the control nodes corresponding to each of the identified
solutions.
All matrix operations use the Math.NET Numerics library [46]. We paral-
lelised the execution of the most used methods, such as chromosome initialisation
or crossover. In turn, this required adapting the default pseudo-random number
generator into a thread-safe version by using a thread-safe collection of seeds
based on the initial random seed.
The graphical interface of the program can be seen in Figure 2. Further
details on the implementation and usage can be found in the supplementary
information and in the GitHub repository ([59]).
Figure 2: The graphical user interface of the program. Top left: The start page.
Top right: The form to create a new analysis. Bottom left: The dashboard
containing the list of analyses. Bottom right: The details of an analysis.
3 Results
3.1 Benchmark data
We applied the algorithm on several real world and randomly generated complex
networks. The size of the networks varied from 32 to over 3000 nodes. An
overview of the data sets is presented in Table 2. We used the breast, pancre-
atic, and ovarian cancer cell line-specific protein-protein interaction networks
documented in [36]. We also used the breast, pancreatic, and ovarian cancer
networks of [38]. We also considered several social interaction networks and
electronic circuit networks documented in [50] and [49]. Finally, we generated
several random graphs with the number of nodes ranging from 100 to 3000
and the edges distributed according to the Erdo¨s-Re´nyi-, scale-free-, and small
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world-graph edge distributions, all of them generated using the Python networkx
library ([72]). All networks are available as supplementary information.
For the protein-protein interaction networks we used as target nodes the
cancer essential genes specific to each cell line, based on [38]. For the other
networks, as target nodes we chose the top 5% nodes with highest degree.
3.2 The comparison setup
All runs were executed with the same default values for the parameters of
the algorithm, as detailed in Table 1. The algorithm was stopped after 1,000
generations with no improvement in the fitness of the best solution, up to a
maximum of 10,000 generations. The results are presented in Table 3 and in the
supplementary data.
In addition, we applied the algorithm one more time on the protein-protein
interaction networks, considering as preferred nodes the FDA approved drug-
targets ([75]) existent in the network. The results are presented in Table 4 and
in the supplementary data.
We compared the results of our genetic algorithm to the results of the
greedy algorithm described in [13], applied on the same data sets. To make the
comparison possible, we limited both algorithms to running for a maximum of
10,000 total iterations (translated to 10,000 generations for the genetic algorithm),
stopping if there was no improvement in the best result over the past 1,000
iterations / generations. To investigate the effect of the limited length pathways
in our algorithm, we ran the greedy algorithm in two different settings: with the
control path’s length upper bounded by the same parameter as in the genetic
algorithm, and with it unconstrained.
The three algorithms work quite differently, not only in their inner logic
for optimising the objective, but also in their output. The genetic algorithm
maintains in each step of its search a family of solutions, some better than others
(from the point of view of the optimisation problem to be solved), but all valid
solutions in terms of controlling the given set of targets. Thus, each run of
the genetic algorithm offers as an output several different solutions. This is in
contrast with the greedy algorithms, where only one solution is found in one
run and multiple runs have to be done to collect multiple solutions (of variable
optimisation quality).
3.3 The comparison results
The first benchmark objective we compared against was the size of the smallest
set of input nodes found by each of the three algorithms, with the smallest being
the best. The results are presented in Table 3.
We also compared the running time required by the algorithms to complete
on each of the benchmark networks and the speed of convergence towards a good
solution. The results, reported as running time per solution and convergence
speed are in Figures 3 and 4.
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Figure 3: A comparison between the results of the three algorithms: the running
time per solution. The data is displayed on logarithmic scale.
Finally, we compared the ability of the three algorithms to maximise the use
of preferred nodes. We did this on the biological networks, with the preferred
nodes being the set of FDA-approved drug targets. We also did a literature-based
validation of the relevance of the results found by the genetic algorithm in each
of the cancer networks. The results are in Tables 4, 5 and 6.
4 Discussion
We applied the algorithm on a series of networks ranging from a few tens of
nodes, to several thousands of them. For each such network size, we analysed
several network types (real-life, random, scale-free, small world), each with a
varying number of edges and target nodes. The running times ranged from a
few seconds on the smaller networks, up to several hours on the bigger ones.
Size of the best solutions
In the case of the cancer protein-protein interaction networks, the genetic
algorithm returned input sets of size 10 − 25% smaller than the constrained
greedy algorithm and 10− 20% smaller than the general greedy algorithm. The
comparison can be seen in Figure 5.
In the case of the non-biological networks, the size of the smallest input sets
is virtually identical in the three algorithms, even though the sets themselves
may be different.
An interesting aspect can be seen in the analyses of the well-connected
Erdo¨s-Re´nyi and small world random networks, where the genetic algorithm
succeeds in finding the optimal solution. To see this, let’s consider the case of
the largest small world benchmark network. The maximum path length being
set at 50 means that a given input node can control at most 51 nodes in the
12
Figure 4: The average and best fitness of the chromosomes over the generations
in the case of the largest benchmark protein-protein interaction network.
network (itself, and 50 others, through consecutive edges). Thus, for a set of 150
target nodes, there have to be at least
[
150
51
]
+ 1 = 3 input nodes. The genetic
algorithm indeed identifies exactly 3 input nodes, with a maximum length of the
control path of 49. The general greedy algorithm, being allowed to use longer
control paths, identified one input node that controls the entire target set, at
the cost of an increased maximum path length of 149 and a running time 40
times longer.
Running times and convergence speed
A big difference in the results was in the running time of the algorithms to
complete. The genetic algorithm was the fastest algorithm in the random Erdo¨s-
Re´nyi networks, in the random small world networks, and in some of the real-life
non-biological networks. For the biological and the scale-free networks the fastest
was the constrained greedy algorithm, with the genetic algorithm the slowest
of the three, and in general 2-4 times slower than the general greedy algorithm.
However, the genetic algorithm provides simultaneously several solutions (in our
benchmarks tests we set the population size parameter to 80), a key advantage of
this method. Because of this, the comparison of the running times per solution
shows the genetic algorithm to be the fastest of the three in all except a handful
of examples, see Figure 3. Compared to the general greedy algorithm, the
running times per solution of the genetic algorithm were up to 10,000 times
faster, except in the case of two networks (one biological, the other a random
scale-free) where the greedy algorithm seemed to stumble almost immediately on
a solution. Compared to the constrained greedy algorithm, the genetic algorithm
was 10-5,000 times faster per solution, except in the case of the the biological
networks (where it was about 2-4 times slower) and the same scale-free random
network where the generic greedy also performed unusually well.
The setup in which we ran the genetic algorithm was to search thoroughly for
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Figure 5: A comparison between the results of the three algorithms: the number
of input nodes controlling the set of disease-specific essential genes in each of
the biological benchmark networks.
a good solution through 10,000 generations. We compared the evolution of the
quality of the solutions throughout the generations and we noticed that a good
solution (i.e., a solution with the fitness within 10% of the solution obtained after
10,000 generations) is in fact achieved very quickly, typically within a few tens of
generations from the start. Figure 4 illustrates the average and best fitness of the
chromosomes in each generation of the algorithm on the largest protein-protein
interaction network in the data set. This suggests that the genetic algorithm
may be applied successfully with a much lower number of generations, perhaps
as low as 100, adding a considerable speed-up to it.
Maximising the number of preferred nodes
We applied the three algorithms on the biological networks with the additional
optimisation objective of maximising the selection as input nodes of FDA-
approved drug targets in the network (preferred nodes). In all cases, the sets of
input nodes returned by the genetic algorithm contained more preferred nodes
than the ones returned by the other algorithms (Figure 6), with a running time
per solution similar to that of the constrained greedy and better than that of the
general greedy algorithm (Figure 7). Even more, the percentage of the preferred
nodes relative to the size of the input nodes in the best solution was in general
two to four times higher in the case of the genetic algorithm (Figure 8). This
led to more control target nodes being controlled by preferred nodes (Figure
9), i.e., leading to predictions of potentially more efficient drugs. This has as
a consequence a clear improvement in the applicability of the algorithm in the
biomedical domain for drug repurposing, an aspect that we discuss next.
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Figure 6: The number of preferred (FDA-approved drug targets) nodes in the
best solution found by each of the three algorithms.
Therapeutically-relevant findings
We analysed in details the FDA-approved drug targets predicted by our algorithm
to control the most essential genes in each of our network. The results are
presented in Table 5. We used the public DrugBank database [75] to find drugs
targeting the proteins in Table 5 and known to be used in cancer therapeutics.
The results are presented in the Table 6.
Out of the seven top controlling proteins for the analysed breast cancer net-
works, four proteins are known to be of significance in breast cancer proliferation:
EGFR ([5, 54, 9]), AURKB ([25]), RAF1 ([40, 48, 6]) and SRC ([58, 53, 32]).
These proteins are targetted by several FDA-approved and investigational drugs
used in fighting breast cancer (lapatinib, vandetanib, canertinib, varlitinib, KX-01,
dasatinib). Additionally, two other drugs targetting the same proteins are inves-
tigated for use in treating unspecified cancer types (LErafAON, XL281 ). Two of
the other top controlling proteins, RET and MTCP1, are known to be significant
in other types of cancer, such as ovarian cancer ([24]), pancreatic cancer ([16]),
prostate cancer ([71]) or brain cancer ([27]). Even more, there already exists an
FDA-approved breast cancer drug targeting these proteins (selpercatinib), as well
as several approved and investigational drugs used for treating other cancer types
(ponatinib, sorafenib, sunitinib, cabozantinib, amuvatinib). In particular, the
drug sorafenib, used for the treatment of kidney and liver cancers, targets two of
our top four controlling proteins, which may indicate its potential use in breast
cancer as well. Indeed, there are several completed clinical trials researching
the drug in the treatment of breast cancer ([10, 55]). Additionally, the drug
cabozantinib is also on trial for breast cancer treatment ([45, 14]). Among the
top controlling proteins was also PLRG1, for which no drug exists, marking it
as a potential drug-target for future research.
For the analysed ovarian cancer networks, the algorithm identified six top
controlling proteins. Three of these are documented as being of significance in
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Figure 7: The runtime for finding preferred (FDA-approved drug targets) nodes
in the best solution found by each of the three algorithms. The data is displayed
on logarithmic scale.
ovarian cancer: TGFB1 ([66, 19]), SRC ([39, 28, 74]) and MAPK3 ([64, 77, 12]),
with several drugs targeting these proteins already approved or being under
investigation for various types of cancer treatment (dasatinib, XL228, seliciclib,
ulixertinib, ponatinib, nintedanib). Furthermore, the other three top controlling
proteins, SET, LCK and CSNK2A1, are significant in other cancer types, such
as leukemia ([31, 33]), colorectal cancer ([11, 20]) and prostate cancer ([1]).
For the pancreatic cancer networks analysed by the algorithm, we identified
eleven top controlling proteins. Five of them are known to be significant in pan-
creatic cancer: IGF1R ([18, 81, 78]), ERBB4 ([30]), KRAS ([8, 65, 17]), ERBB2
([4, 69, 56]) and MTOR ([44, 80, 29]) and targeted by several FDA-approved and
investigational cancer drugs (XL228, rhIGFB-3, linsitinib, brigatinib, SF1126,
XL765, ridaforolimus). Four of the other identified top controlling proteins,
ABL1, PDPK1, CSNK2A1 and CDK1 are documented as significant in other
types of cancer, for example breast cancer ([34, 68]) and prostate cancer ([1, 76]).
They are, as well, targeted by several drugs under investigation for treating
cancer (AT-7519, seliciclib). In particular, the drug brigatinib could be especially
powerful in this case, as it targets four of the eleven top controlling proteins
(ABL1, IGF1R, ERBB4, ERBB2 ). Another interesting case is the non-steroidal
anti-inflammatory drug celecoxib targeting PDPK1, used to manage symptoms
of arthritis pain and in familial adenomatous polyposis, which has also been
under investigation as potential cancer chemo-preventive and therapeutic drug
[23]. Indeed, there are several ongoing and completed trials researching the effect
of the drug in pancreatic cancer ([63, 47]). Among the top controlling proteins
were also PPP2R1A and DUSP7, for which no drug exists, marking them as
well as potential drug-targets for future research.
Furthermore, we found the drug fostamatinib, used for the treatment of
rheumatoid arthritis and immune thrombocytopenic purpura, which targets five
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Figure 8: The percentage of preferred (FDA-approved drug targets) nodes in
the best solution found by each of the three algorithms.
out of the seven top controlling proteins for breast cancer, four out of the six for
ovarian cancer, and seven out of the eleven for pancreatic cancer. Our algorithm
thus suggests that the drug could potentially be used in cancer treatment. This
idea is supported by several completed clinical trials for using fostamatinib in
treating lymphoma ([2, 61]) and one ongoing trial for ovarian cancer ([67]).
Conclusions
In this paper we proposed a new solution for the target network controllability
problem. Our search strategy is based on a genetic algorithm, where the
population in each generation of the training of the algorithm is a set of valid
solutions to the network controllability problem. The algorithm turns out to be
scalable, with its performance staying strong even for very large networks.
The number of edges in a network alone does not seem to influence the
performance of the algorithm. The increase in the running time as the network
size increases, is mainly caused by the increasing number of nodes and target
nodes. This makes the genetic algorithm optimally suited to be applied on very
large networks, where many solutions need to be collected.
The genetic algorithm provides, at every step, a family of solutions, while
the greedy algorithms offer only one. This is a key advantage of this algorithm,
especially for drug repurposing applications, where multiple alternative solutions
are important to collect and compare.
The genetic algorithm comes by design with a set-limit on the maximum
length of control paths from the input to the target nodes. This is a feature
that is of particularly important interest in applications in medicine, where the
effects of a drug dissipate quickly over longer signalling paths. The focused
search upstream of the target nodes led to the genetic algorithm drastically
improving the percentage of FDA-approved drug targets selected in its solution,
a clear step forward towards applications in combinatorial drug selection and
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Figure 9: The number of essential genes controlled by the preferred (FDA-
approved drug targets) nodes in the best solution found by each of the three
algorithms.
drug repurposing. The drugs identified by our algorithm as potentially efficient
for breast, ovarian, and pancreatic cancer correlate well with recent literature
results, and some of our suggestions have already been subject to several clinical
studies. This strengthens the potential of our approach for studies in synthetic
lethality-driven drug repurposing.
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Parameter Meaning Type Default
value
N Total number of generations for
which the algorithm will run
N ∈ N≥1 N = 10000
n Total number of chromosomes
in a generation
n ∈ N≥2 n = 80
pm Probability of mutation for a
chromosome
pe ∈ R[0,1] pm = 0.25
pe Maximum percentage of elites
in a generation
pr ∈ R[0,1] pe = 0.01
pr Percentage of randomly
generated chromosomes in a
generation
pm ∈ R[0,1] pr = 0.25
maxpath Maximum number of
interactions in a control path
maxpath ∈
N≥1
maxpath =
5
maxrand Maximum number of randomly
generated genes in a
chromosome
maxrand ∈
N≥1
maxrand =
15
Table 1: The parameters used by the genetic algorithm. N represents the
maximum number of generations for which the algorithm will run. Additionally,
the algorithm will stop after 1000 generations with no improvement in the fitness
of the best chromosomes. Higher values for N improve the chances of getting
better results, but increase the overall running time. n represents the total
number of chromosomes in a generation. This includes randomly generated
chromosomes, elite chromosomes of the previous generation, as well as offspring
of the chromosomes in the previous generation. Higher values result in a larger
population, thus increasing the gene pool, however it might spread the search
space too much, getting the process closer to a random search. pm represents the
probability of mutation for a chromosome. It is defined for an entire chromosome,
and not for a particular gene. Increasing its value will help with the exploration
of the solution space, but too much will make the process get closer to a random
search. A value of 0 will deactivate the mutation operator. pe represents the
percentage of elite chromosomes in a population. Higher values will increase the
number of preserved chromosomes with high fitness score over the generations,
but the solution space will get smaller. A value of 0 will deactivate elitism.
pr represents the percentage of new randomly generated chromosomes in a
population. Higher values will increase the exploration of the solution space, but
it will also be getting the process closer to a random search. A value of 0 will
deactivate this feature.
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Type Network Reference Nodes Edges
Protein-protein
interaction
Breast DEF [36] 1415 2435
Protein-protein
interaction
Breast
HCC1428
[38] 1495 2650
Protein-protein
interaction
Breast
MDA-MB-361
[38] 1478 2590
Protein-protein
interaction
Ovarian DEF [36] 1047 1579
Protein-protein
interaction
Ovarian O1946 [38] 1155 1823
Protein-protein
interaction
Ovarian
OVCA8
[38] 1157 1781
Protein-protein
interaction
Pancreatic
AsPC-1
[38] 1022 1534
Protein-protein
interaction
Pancreatic DEF [36] 991 1484
Protein-protein
interaction
Pancreatic
KP-3
[38] 1134 1757
Protein-protein
interaction
SIGNOR
BrOvPa DEF
[36] 2913 6729
Social Social
Interaction 1
[49] 67 182
Social Social
Interaction 3
[49] 32 96
Electronic
circuit
Electronic
circuit 208
[50] 122 189
Electronic
circuit
Electronic
circuit 420
[50] 208 189
Electronic
circuit
Electronic
circuit 838
[50] 512 819
ErdsRnyi Erdos-Renyi
100
* 62 47
ErdsRnyi Erdos-Renyi
500
* 497 1270
ErdsRnyi Erdos-Renyi
1000
* 1000 4952
To be continued.
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Type Network Reference Nodes Edges
ErdsRnyi Erdos-Renyi
1500
* 1500 11258
ErdsRnyi Erdos-Renyi
2000
* 2000 19869
ErdsRnyi Erdos-Renyi
2500
* 2500 30976
ErdsRnyi Erdos-Renyi
3000
* 3000 44713
Scale-free Scale Free 100 ** 100 166
Scale-free Scale Free 500 ** 500 816
Scale-free Scale Free 1000 ** 1000 1793
Scale-free Scale Free 1500 ** 1500 2526
Scale-free Scale Free 2000 ** 2000 3401
Scale-free Scale Free 2500 ** 2500 4316
Scale-free Scale Free 3000 ** 3000 5236
Small world Small World
100
*** 100 400
Small world Small World
500
*** 500 2000
Small world Small World
1000
*** 1000 4000
Small world Small World
1500
*** 1500 6000
Small world Small World
2000
*** 2000 8000
Small world Small World
2500
*** 2500 10000
Small world Small World
3000
*** 3000 12000
Table 2: The data sets used for testing the algorithm ([59]). * Generated
in Python, using networkx.generators.random graphs.fast gnp random graph
with p = 0.005. ** Generated in Python, using
networkx.generators.directed.scale free graph with the de-
fault parameters. *** Generated in Python, using net-
workx.generators.random graphs.watts strogatz graph with k = 4 and
p = 0.2. All isolated nodes were removed from the networks.
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Network N E T Ige Igc Igr
Breast DEF 1415 2435 112 57 74 73
Breast HCC1428 1495 2650 126 64 82 80
Breast
MDA-MB-361
1478 2590 124 61 80 77
Ovarian DEF 1047 1579 140 92 112 111
Ovarian O1946 1155 1823 159 108 120 120
Ovarian OVCA8 1157 1781 161 99 116 115
Pancreatic AsPC-1 1022 1534 125 78 93 91
Pancreatic DEF 991 1484 168 109 131 131
Pancreatic KP-3 1134 1757 167 103 128 126
SIGNOR BrOvPa
DEF
2913 6729 145 68 90 82
Social Interaction 1 67 182 14 1 1 1
Social Interaction 3 32 96 7 2 3 3
Electronic Circuit
208
122 189 25 1 3 3
Electronic Circuit
420
208 189 42 25 25 25
Electronic Circuit
838
512 819 103 3 15 14
Erdos-Renyi 100 62 * 47 5 4 4 4
Erdos-Renyi 500 497 * 1270 25 1 4 4
Erdos-Renyi 1000 1000 4952 50 1 2 1
To be continued.
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Network N E T Ige Igc Igr
Erdos-Renyi 1500 1500 11258 75 2 3 1
Erdos-Renyi 2000 2000 19869 100 2 4 1
Erdos-Renyi 2500 2500 30976 125 3 4 1
Erdos-Renyi 3000 3000 44713 150 3 7 1
Scale Free 100 100 166 5 2 2 2
Scale Free 500 500 816 25 17 17 17
Scale Free 1000 1000 1793 50 37 38 38
Scale Free 1500 1500 2526 75 60 61 61
Scale Free 2000 2000 3401 100 71 72 72
Scale Free 2500 2500 4316 125 93 94 94
Scale Free 3000 3000 5236 150 94 96 96
Small World 100 100 400 5 1 1 1
Small World 500 500 2000 25 1 1 1
Small World 1000 1000 4000 50 1 3 1
Small World 1500 1500 6000 75 2 5 1
Small World 2000 2000 8000 100 2 7 1
Small World 2500 2500 10000 125 3 9 1
Small World 3000 3000 12000 150 3 12 1
Table 3: The results of the algorithm. N: the number of nodes in the network;
E: the number of edges in the network; T: the number of target nodes in the
network: I: the smallest number of input nodes found for controlling the control
target set by the respective algorithm, i.e., Ige for the genetic algorithm, Igc for
the constrained greedy algorithm, and Igr for the general (unconstrained) greedy
algorithm. * The nodes without any inbound or outbound edge are not counted.
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Network N E T P Ige IPge Igc IPgc Igr IPgr
Breast DEF
(drug)
1415 2435 112 123 61 13 74 6 73 5
Breast
HCC1428
(drug)
1495 2650 126 135 63 10 82 7 80 5
Breast
MDA-MB-
361
(drug)
1478 2590 124 136 63 13 80 5 77 4
Ovarian
DEF (drug)
1047 1579 140 100 94 10 112 7 111 6
Ovarian
O1946
(drug)
1155 1823 159 104 108 18 120 10 119 11
Ovarian
OVCA8
(drug)
1157 1781 161 105 101 15 115 11 115 10
Pancreatic
AsPC-1
(drug)
1022 1534 125 90 73 7 93 5 91 4
Pancreatic
DEF (drug)
991 1484 168 86 120 18 131 10 131 9
Pancreatic
KP-3
(drug)
1134 1757 167 94 104 15 128 8 126 8
SIGNOR
BrOvPa
DEF (drug)
2913 6729 201 145 80 19 91 4 82 1
Table 4: The results of the algorithm. N: the number of nodes in the network;
E: the number of edges in the network; T: the number of control target nodes
in the network; P: the number of preferred (i.e., drug-targetable) nodes in the
network; I: the smallest number of input nodes found for controlling the control
target set; IP the number of preferred input nodes in the best solution; ge:
the results for the genetic algorithm; gc: the results for the constrained greedy
algorithm;gr: the results for the general (unconstrained) greedy algorithm.
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Breast Ovarian Pancreatic
RET (5)
EGFR (6)
MTCP1 (5)
AURKB (6)
RAF1 (5)
SRC (5)
PLRG1 (2)
TGFB1 (5)
SRC (5)
SET (5)
LCK (5)
MAPK3 (6)
CSNK2A1 (5)
IGF1R (6)
ERBB4 (5)
KRAS (6)
ABL1 (6)
PDPK1 (5)
PPP2R1A (5)
DUSP7 (5)
ERBB2 (5)
CSNK2A1 (5)
CDK1 (6)
MTOR (6)
Table 5: The proteins that control the most target proteins, for each cancer type.
In bold letters: proteins that are known to be of significance in the corresponding
cancer type. In italic letters: proteins that are known to be of significance in
other cancer types. In brackets: number of target proteins controlled by the
protein by itself (the sets of target proteins controlled by different proteins might
overlap).
Breast Ovarian Pancreatic
amuvatinib
cabozantinib
canertinib
dasatinib
fostamatinib
KX-01
lapatinib
LErafAON
ponatinib
selpercatinib
sorafenib
sunitinib
vandetanib
varlitinib
XL281
dasatinib
fostamatinib
nintedanib
ponatinib
seliciclib
ulixertinib
XL228
AT-7519
brigatinib
celecoxib
fostamatinib
linsitinib
rhIGFBP-3
ridaforolimux selici-
clib
SF1126
XL228
XL765
Table 6: The drugs that target the identified control proteins. In bold letters:
drugs approved or under investigation for usage in the treatment of the corre-
sponding cancer type. In italic letters: drugs under investigation for treatment
of other or unspecified cancer or tumour types.
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